<SEC-DOCUMENT>0001193125-16-787564.txt : 20161207
<SEC-HEADER>0001193125-16-787564.hdr.sgml : 20161207
<ACCEPTANCE-DATETIME>20161207171556
ACCESSION NUMBER:		0001193125-16-787564
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20161207
DATE AS OF CHANGE:		20161207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-194126
		FILM NUMBER:		162039891

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d270346d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-194126 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
April&nbsp;29, 2016) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$75,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g270346g56s59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Sangamo BioSciences, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a sales
agreement with Cowen and Company, LLC (Cowen), relating to shares of our common stock, $0.01 par value per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock
having an aggregate offering price of up to $75,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves a high degree of risk. See &#147;Risk Factors&#148;
beginning on page S-6 of this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Market under the symbol &#147;SGMO.&#148; On
December&nbsp;6, 2016, the last reported sale price of our common stock on The NASDAQ Global Market was $3.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon our delivery of a placement
notice and subject to the terms and conditions of the sales agreement, Cowen may sell our common stock by methods deemed to be an &#147;at the market offering&#148; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended
(Securities Act), including sales made directly on The NASDAQ Global Market, on any other existing trading market for our common stock or to or through a market maker. In addition, with our prior written approval, Cowen may also sell our common
stock in negotiated transactions. Cowen will act as sales agent using its commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cowen and us. There is no arrangement for funds to be
received in any escrow, trust or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Cowen a commission, or allow a discount, for its services in acting as agent and/or
principal in the sale of common stock equal to 3.0% of the gross sales price per share of all shares sold through it as agent under the sales agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of common stock on our behalf, Cowen may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and
the compensation to Cowen will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cowen with respect to certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. Please read the information contained in and incorporated by reference under the heading
&#147;<A HREF="#supptoc270346_3">Risk Factors</A>&#148; beginning on page S-6 of this prospectus supplement, the sections captioned &#147;Risk Factors&#148; in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q,
which are incorporated by reference into this prospectus supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Cowen and
Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">December&nbsp;7, 2016 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc"></A>Table of Contents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_2">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_5">Use Of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_8">Market for Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_9">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_11">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_12">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc270346_13">Incorporation Of Certain Documents By Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_2">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_3">About Sangamo BioSciences, Inc.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_5">Use Of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_6">Ratio Of Earnings To Fixed Charges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_7">Plan Of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_8">The Securities We May Offer</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_9">Description Of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_10">Description Of Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_11">Description Of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_12">Description Of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_13">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_15">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_16">Incorporation Of Certain Documents By Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus dated April&nbsp;29, 2016 is part of a &#147;shelf&#148; registration statement on
Form S-3 we initially filed on February&nbsp;25, 2014 with the Securities and Exchange Commission which became effective on the same date, and was subsequently amended and became effective on April&nbsp;29, 2016. By using a &#147;shelf&#148;
registration statement, we may sell shares of common stock, preferred stock, debt securities, warrants to purchase common stock and/or warrants to purchase preferred stock, as described in the accompanying prospectus, from time to time in one or
more offerings, of which an aggregate of $75 million may be sold in this offering in the form of shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is
in two parts. The first part is this prospectus supplement, which describes the specific terms of this common stock offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by
reference herein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the
information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the
information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in the accompanying
prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We further note that
the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some
cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date
when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus supplement or the accompanying prospectus, or incorporated by reference
herein. We have not authorized, and Cowen has not authorized, anyone to provide you with information that is different. The information contained in this prospectus supplement or the accompanying prospectus, or incorporated by reference herein, is
accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock. It is important for you to read and consider all information
contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to
which we have referred you in the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement and in the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The
distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus
supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United
States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the
accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, all references in this prospectus supplement and the accompanying prospectus to &#147;we,&#148; &#147;us,&#148;
&#147;our,&#148; &#147;Sangamo,&#148; the &#147;Company&#148; and similar designations refer to Sangamo BioSciences, Inc. and its subsidiaries on a consolidated basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by
reference in this prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and
this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information referred to under the heading &#147;Risk Factors&#148; in this
prospectus supplement beginning on page S-6, the information incorporated by reference in this prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have authorized for use in
connection with this offering. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are the leading company in
the field of therapeutic genome editing which we are applying to &#147;Engineer Genetic Cures<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#148; for numerous gene-based diseases. As a clinical stage biopharmaceutical company we are
focused on the development of gene therapies including the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation.&nbsp;Our proprietary zinc finger DNA-binding protein (ZFP)
technology enables efficient and highly specific genome editing and gene regulation and we are developing ZFP Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and gene therapies for the treatment of genetic disease. We have
several proprietary clinical and preclinical programs in development and have strategically partnered certain programs with biopharmaceutical companies to obtain funding for our own programs and to expedite clinical and commercial development. Our
long-term goal is to forward integrate into manufacturing, development and commercial operations to more fully capture the value of our proprietary ZFP Therapeutic and gene therapy products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and our licensed partners, are the leaders in the research, development and commercialization of ZFPs, a naturally occurring class of
proteins found in humans. We have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make ZFP nucleases (ZFNs), proteins that can be used to
specifically modify DNA sequences by adding or knocking out specific genes (genome editing) and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off (gene regulation). As ZFPs act at the DNA level, they potentially
have broad and fundamental applications in several areas, including human therapeutics, plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering. In the process of developing this platform we
have accrued significant scientific, manufacturing and regulatory capabilities and know-how that is generally applicable in the broader field of gene therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main focus for our company is the development of novel human therapeutics. We have initiated a Phase 1/2 study of an <I>in vivo</I>
ZFN-mediated genome editing application for the treatment of hemophilia B and expect to initiate Phase 1/2 studies of similar approaches for the treatment of Mucopolysaccharidosis I (MPS I) and Mucopolysaccharidosis II (MPS II), which are lysosomal
storage disorders (LSD). We also have plans to initiate a Phase 1/2 AAV Factor 8 cDNA gene therapy program for hemophilia A. In addition, we have ongoing Phase 1/2 and Phase 2 clinical programs to evaluate genome edited autologous hematopoietic stem
cell and T-cell products, respectively, for the treatment of HIV/AIDS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have additional proprietary preclinical programs in hemophilia
A and other LSDs and research stage programs in other monogenic diseases, certain central nervous system (CNS) disorders and cancer immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a strategic collaboration with Bioverativ, the planned spin-off company of Biogen, Inc., for rare blood disorders, for the
development of ZFP Therapeutics for hemoglobinopathies, including sickle cell disease and beta-thalassemia. We also have a collaborative partnership with Shire International GmbH, formerly Shire AG, to research, develop and commercialize our
preclinical ZFP Therapeutic development program in Huntington&#146;s disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into strategic partnerships in fields
outside human therapeutics to facilitate the sale or licensing of our ZFP platform. We have a license agreement with Sigma-Aldrich Corporation (Sigma). Under this agreement, Sigma has the exclusive rights to develop and market ZFP-based laboratory
research reagents marketed </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the trademark CompoZr&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and
ZFP-engineered transgenic animals. We also have a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under this agreement, DAS has the exclusive rights to use our ZFP technology to modify the
genomes or alter protein expression of plant cells, plants, or plant cell cultures and markets our ZFN technology under the trademark EXZACT<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>&nbsp;Precision Technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a substantial intellectual property position in the genome editing field including the design, selection, composition and use of
engineered ZFPs to support our commercial activities. As of December&nbsp;5, 2016, we either owned outright or have exclusively licensed the commercial rights to approximately 751 patents issued in the United States and foreign national
jurisdictions, and we had 675 patent applications owned and licensed pending worldwide. We continue to license and file new patent applications that strengthen our core and accessory patent portfolio. We believe that our intellectual property
position is a critical element in our ability to research,&nbsp;develop and commercialize products and services based on ZFP technology across our chosen applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the development of our ZFP technology platform, we are focusing our resources on higher-value ZFP Therapeutic product development and less
on our non-therapeutic applications. Development of novel therapeutic products is costly and is subject to a lengthy and uncertain regulatory process at the FDA. Our future products will be gene-based therapeutics. Adverse events in both our own
clinical program and other programs may have a negative impact on regulatory approval, the willingness of potential commercial partners to enter into agreements and public perception. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>An investment in our
common stock is subject to a number of risks and uncertainties<I>. </I>Before investing in our common stock, you should carefully consider the following, as well as the more detailed discussion of risk factors and other information included in this
prospectus supplement:<I> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ZFP Therapeutics have undergone limited testing in humans and our ZFP Therapeutics may fail safety studies in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our progress in early Phase 1 and Phase 2 trials may not be indicative of long-term efficacy in late stage clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process, and we may encounter unanticipated toxicity or adverse events or fail to demonstrate efficacy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">While we have stated that we intend to file IND applications for several ZFP Therapeutic programs in the future, we may encounter difficulties that may delay, suspend or scale back our efforts; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not be able to find acceptable patients or may experience delays in enrolling patients for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, we cannot predict the timing of any future revenue from these product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited experience in conducting clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Regulatory approval, if granted, will be limited to specific uses or geographic areas, which could limit our ability to generate revenues; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not find partners in the future to develop our technologies or products or our partners may not diligently pursue our product development efforts. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company and Other Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Our
principal offices are located at 501 Canal Boulevard, Richmond, California, 94804, and our telephone number there is (510)&nbsp;970-6000<I>. </I>Our website address is www.sangamo.com<I>. </I>We do not incorporate the <I>
</I></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
</I>information on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this
prospectus<I>. </I>For further information regarding us and our financial information, you should refer to our recent filings with the Securities and Exchange Commission<I>. </I>See &#147;Where You Can Find More Information&#148; and
&#147;Incorporation of Certain Documents by Reference.&#148;<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>ZFP
Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of Sangamo BioSciences, Inc<I>. </I>This prospectus supplement and the accompanying prospectus and information incorporated by reference into this
prospectus supplement and the accompanying prospectus also contain trademarks and trade names that are the property of their respective owners.<I> </I></P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common&nbsp;stock&nbsp;offered&nbsp;by&nbsp;us&nbsp;in&nbsp;this&nbsp;offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shares having an aggregate offering price of up to $75,000,000.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manner of offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;At the market offering&#148; that may be made from time to time through our sales agent, Cowen and Company, LLC. See &#147;Plan of Distribution&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-12.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">We intend to use the net proceeds from this offering for working capital and other general corporate purposes, including support for our continuing research and development of our ZFP Therapeutic product candidates and other
research programs, commercialization activities, clinical trials, business development activities and, if opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to our business. See &#147;Use of
Proceeds&#148; on page S-9.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">You should carefully read &#147;Risk Factors&#148; on page S-6 in this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ Global Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;SGMO&#148;</TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should consider carefully the
risks described below and the risk factors incorporated by reference herein from our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December&nbsp;31, 2015 and our Quarterly Reports on
Forms 10-Q, together with other information in this prospectus supplement, the accompanying prospectus, the information and documents incorporated by reference, and in any free writing prospectus that we have authorized for use in connection with
this offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or
part of your investment. The risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use the proceeds effectively.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Our management will have broad discretion in the application of the net proceeds from this offering and could spend the
proceeds in ways that do not improve our results of operations or enhance the value of our common stock<I>. </I>Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our product
candidates and cause the price of our common stock to decline.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>You will experience immediate and substantial dilution in the
net tangible book value per share of the common stock you purchase. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Since the price per share of our common stock being
offered is substantially higher than the net tangible book value per share of our common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering<I>. </I>Based on the assumed public
offering of 25,000,000 shares at the assumed price of $3.00 per share (the closing sales price on The NASDAQ Global Market on December&nbsp;6, 2016), and without deducting underwriting discounts and commissions but after deducting estimated offering
expenses payable by us, and based on a net tangible book value of our common stock of $2.01 per share as of September&nbsp;30, 2016, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $0.73
per share in the net tangible book value of common stock<I>. </I>See the section entitled &#147;Dilution&#148; below for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Future transactions where we raise capital may negatively affect our stock price. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have the ability to offer and sell additional equity, debt securities and warrants to purchase such securities, either
individually or in units, under an effective automatic shelf registration statement. Sales of substantial amounts of shares of our common stock or other securities under our shelf registration statements could lower the market price of our common
stock and impair our ability to raise capital through the sale of equity securities. In the future, we may issue additional options, warrants or other derivative securities convertible into our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended September&nbsp;30, 2016, the closing price of our common stock, as reported by the NASDAQ Global Market, ranged
from a low of $4.13 to high of $6.84. During the fiscal year ended December&nbsp;31, 2015, our common stock price fluctuated, ranging from a low of $5.56 to a high of $18.54. Volatility in our common stock could cause stockholders to incur
substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response to
various factors, some of which are beyond our control, including but not limited to the following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Announcement by us or collaborators providing updates on the progress or development status of ZFP Therapeutics and our gene therapy products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">data from clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiation or termination of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall market and economic conditions, including the equity markets for emerging biotechnology companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deviations in our results of operations from the guidance given by us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of new or enhanced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement of changes in business and operations by our collaborators and partners, or changes in our existing collaboration agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes, by one or more of Sangamo&#146;s security analysts, in recommendations, ratings or coverage of our stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreases in our cash balances. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_4"></A>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some statements contained in this report are forward-looking with respect to our operations, research,
development and commercialization activities, clinical trials, operating results and financial condition. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or
achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product development and commercialization of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intellectual property position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering, acquisition and other strategic transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revenues from existing and new collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research and development and other expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficiency of our cash resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operational and legal risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans, objectives, expectations and intentions and any other statements that are not historical facts. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as: &#147;anticipates,&#148; &#147;believes,&#148;
&#147;continues,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;seeks,&#148; &#147;should&#148; and &#147;will.&#148; These statements reflect our current views
with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements.&nbsp;We discuss many of these risks in
greater detail under the headings &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Conditions and Results of Operations&#148; in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and we urge
you to review such reports before making any investment decision. Sangamo undertakes no obligation to publicly release any revisions to forward-looking statements to reflect events or circumstances arising after the date of this prospectus
supplement. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;and Engineering
Genetic Cures<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;are registered trademarks of Sangamo BioSciences, Inc. This report also contains trademarks and trade names that are the property of their respective owners </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for working capital and other general corporate purposes, including support for our
continuing research and development of our ZFP Therapeutic product candidates and other research programs, commercialization activities, clinical trials, business development activities, and, if opportunities arise, acquisitions of businesses,
products, technologies or licenses that are complementary to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>The amounts and timing of the expenditures may vary
significantly, depending upon numerous factors, including our proprietary research and therapeutic programs and our clinical trials as well as the amount of cash used in our operations<I>. </I>Accordingly, our management will have broad discretion
in the application of the net proceeds and investors will be relying upon the judgment of our management regarding the application of these proceeds<I>. </I>We reserve the right to change the use of these proceeds.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending these uses, we intend to invest the proceeds of this offering in short-term, investment grade interest -bearing securities. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid dividends on our common stock, and currently do not plan to pay any cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>If you purchase our common stock in this offering, your interest will be diluted to the extent of the difference between the offering
price per share and the net tangible book value per share of our common stock after this offering<I>. </I>Our net tangible book value as of September&nbsp;30, 2016 was approximately $142.3 million, or $2.01 per share<I>. </I>Net tangible book value
per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of September&nbsp;30, 2016<I>. </I>Dilution in net tangible book value per share represents the
difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>After taking into account the assumed sale by us of 25,000,000 shares of our common stock in this offering at the assumed public
offering price of $3.00 per share, the closing price on The NASDAQ Global Market on December&nbsp;6, 2016, without any deduction for underwriting discounts and commissions but after deducting estimated offering expenses payable by us, our as
adjusted net tangible book value as of September&nbsp;30, 2016 would have been approximately $217 million, or $2.27 per share<I>. </I>This would represent an immediate increase in net tangible book value of $0.26 per share to existing stockholders
and in immediate dilution of $0.73 per share to investors purchasing our common stock in this offering at the assumed public offering price<I>. </I>The following table illustrates this dilution on a per share basis:<I> </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes for illustrative purposes that an aggregate of 25,000,000 shares of our common stock
are sold at a price of $3.00 per share, the last reported sale price of our common stock on The NASDAQ Global Market on December&nbsp;6, 2016, for aggregate gross proceeds of approximately $75,000,000. The shares sold in this offering, if any, will
be sold from time to time at various prices to be determined by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>The number of shares of common stock to be
outstanding immediately after this offering used to calculate dilution above assumes that all of the shares offered hereby are sold and is based on 70,621,837 shares of common stock outstanding as of September&nbsp;30, 2016<I>. </I>This number of
shares excludes:<I> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">8,951,908 shares of common stock issuable upon exercise of options outstanding as of September&nbsp;30, 2016, of which 5,788,782 shares are exercisable under our 2013 Stock Incentive Plan, at a weighted average exercise
price of $8.48 per share; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">607,819 shares of common stock issuable upon settlement of outstanding restricted stock units; and </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any outstanding options are exercised, new options are issued under our 2013 Stock Incentive Plan or we otherwise issue
additional shares of common stock in the future, there will be further dilution to new investors. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_8"></A>MARKET
FOR COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares of common stock are traded on The NASDAQ Global Market under the symbol &#147;SGMO.&#148; The transfer
agent for our shares of common stock to be issued in this offering is Computershare. The following table sets forth, for the periods indicated, the high and low intraday sales pricing of our common stock as reported by The NASDAQ Global Market. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;6, 2016, the closing price for the common stock as reported on The NASDAQ Global Market was
$3.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2016, there were approximately 59 stockholders of record, which excludes stockholders whose shares were
held in nominee or street name by brokers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_9"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into a sales agreement with Cowen under which we may issue and sell shares of our common stock having an aggregate gross sales
price of up to $75,000,000 from time to time through Cowen acting as agent. The sales agreement is filed as an exhibit to our Current Report on Form&nbsp;8-K dated December&nbsp;7, 2016 and is incorporated by reference to this prospectus supplement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the sales agreement, Cowen may sell our common stock by
any method permitted by law deemed to be an &#147;at-the-market&#148; offering as defined in Rule&nbsp;415 promulgated under the Securities Act, including sales made directly on the Nasdaq Global Market, on any other existing trading market for our
common stock or to or through a market maker. Cowen may also sell our common stock by any other method permitted by law, including in privately negotiated transactions. We may instruct Cowen not to sell common stock if the sales cannot be effected
at or above the price designated by us from time to time. We or Cowen may suspend the offering of common stock upon notice and subject to other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we wish to issue and sell common stock under the sales agreement, we will notify Cowen of the number of shares to be issued, the
dates on which such sales are anticipated to be made, any minimum price below which sales may not be made and other sales parameters as we deem appropriate. Once we have so instructed Cowen, unless Cowen declines to accept the terms of the notice,
Cowen has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Cowen under the sales agreement to sell our common
stock are subject to a number of conditions that we must meet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay Cowen commissions, in cash, for its services in acting as
agent in the sale of our common stock. Cowen will be entitled to compensation at a fixed commission rate equal to 3% of the gross sales price per share sold. Because there is no minimum offering amount required as a condition to close this offering,
the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse Cowen for certain specified expenses, including the fees and disbursements of its legal counsel, in
an amount not to exceed $50,000. We estimate that the total expenses for the offering, excluding discounts and commissions payable to Cowen under the terms of the sales agreement, will be approximately $240,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for sales of common stock will generally occur on the third business day following the date on which any sales are made, or on some
other date that is agreed upon by us and Cowen in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement will be settled through the
facilities of The Depository Trust Company or by such other means as we and Cowen may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cowen will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the common
stock under the terms and subject to the conditions set forth in the sales agreement. In connection with the sale of the common stock on our behalf, Cowen may be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and
the compensation of Cowen will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cowen against certain civil liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of our common stock pursuant to the sales agreement will terminate upon the earlier of (1)&nbsp;the sale of all shares of our
common stock subject to the sales agreement, or (2)&nbsp;termination of the sales agreement as permitted therein. We and Cowen may each terminate the sales agreement at any time upon 10&nbsp;days&#146; prior notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cowen and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our
affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation&nbsp;M, Cowen will not engage in any market making activities involving our common stock while the offering is ongoing under this
prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legality of the common stock offered by this prospectus supplement has been passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP,
San Francisco, California. Cowen and Company, LLC is being represented in connection with this offering by Proskauer Rose LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2015, as set forth in their reports, which are incorporated by reference in this
prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a &#147;shelf&#148; registration statement with the Securities and Exchange Commission, or the Commission, covering the shares
of common stock we are offering under this prospectus supplement. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration
statement. For further information with respect to us and the securities we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the Commission. You may read and copy any document
we file at the Commission&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the Public Reference Room. Our public filings, including reports, proxy and
information statements, are also available on the Commission&#146;s web site at <U>http://www.sec.gov</U>. We maintain a website at <U>www.sangamo.com</U>. The information contained on our website is not incorporated by reference in this prospectus
supplement or the accompanying prospectus, and you should not consider it a part of this prospectus supplement or the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc270346_13"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Commission allows us to &#147;incorporate by reference&#148; information from other documents that we file with them, which means that we
can disclose important information by referring to those documents. The information incorporated by reference is considered to be part of this prospectus supplement and the accompanying prospectus, and information that we file later with the
Commission will automatically update and supersede this information. We incorporate by reference into this prospectus supplement and the accompanying prospectus the documents listed below, and any future filings (other than the portions thereof
deemed to be &#147;furnished&#148; to the Commission pursuant to Item&nbsp;2.02 or Item&nbsp;7.01 of Current Report on Form 8-K) we make with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended,
prior to the termination of this offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our annual report on Form 10-K for the year ended December&nbsp;31, 2015, filed with the Commission on February&nbsp;18, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our quarterly report on Form 10-Q for the quarters ended September&nbsp;30, 2016,&nbsp;June&nbsp;30, 2016 and March&nbsp;31, 2016, filed with the Commission on October&nbsp;27, 2016,&nbsp;August&nbsp;4, 2016 and
May&nbsp;5, 2016, respectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our current reports on Form 8-K filed with the SEC on December&nbsp;7, 2016,&nbsp;October&nbsp;18, 2016,&nbsp;July&nbsp;8, 2016,&nbsp;June&nbsp;15, 2016,&nbsp;June&nbsp;1, 2016 and March&nbsp;18, 2016;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our definitive proxy statement filed in connection with our 2016 Annual Meeting of Stockholders filed with the Commission on April&nbsp;25, 2016; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form 8-A filed under Section&nbsp;12(g) of the Securities Exchange Act of 1934, as amended, with the Commission on March&nbsp;31, 2000,
including any amendment or reports filed for the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any statement in
this prospectus supplement or the accompanying prospectus is inconsistent with any statement that is incorporated by reference and that was made on or before the date of this prospectus supplement or the accompanying prospectus, the statement in
this prospectus supplement or the accompanying prospectus shall supersede such incorporated statement. The incorporated statement shall not be deemed, except as modified or superseded, to constitute a part of this prospectus supplement, the
accompanying prospectus or the registration statement. Statements contained in this prospectus supplement and the accompanying prospectus as to the contents of any contract or other document are not necessarily complete and, in each instance, we
refer you to the copy of each contract or document filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to
each person, including any beneficial owner of our securities, to whom a copy of this prospectus supplement and the accompanying prospectus is delivered, upon written or oral request, a copy of the information that has been incorporated into this
prospectus supplement and the accompanying prospectus by reference (except exhibits, unless they are specifically incorporated into this prospectus supplement and the accompanying prospectus by reference). You should direct any requests for copies
to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo BioSciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">501 Canal Boulevard, Suite
A100 Richmond, CA 94804 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(510)&nbsp;970-6000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$100,000,000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell from time to time shares of common stock, shares of preferred stock, debt securities or warrants to purchase shares of
common stock or shares of preferred stock. We may sell any combination of the above described securities, in one or more offerings in amounts, at prices and on terms determined at the time of the offering. We refer to the shares of common stock,
shares of preferred stock, debt securities and warrants to purchase shares of common stock or shares of preferred stock collectively as the &#147;securities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities that we may offer. Each time we sell securities, we will provide a
prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add information or update information contained in this prospectus. You should read both this prospectus and any
prospectus supplement together with the documents incorporated by reference and described under the heading &#147;Where You Can Find More Information&#148; before you make your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will sell the securities to underwriters or dealers, through agents, or directly to investors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>An investment in the securities offered under this prospectus involves a high degree of risk. You should carefully consider the risk
factors described in the applicable prospectus supplement and certain of our filings with the Securities and Exchange Commission, as described under &#147;<U><A HREF="#toc270346_4">Risk Factors</A></U>&#148; on page&nbsp;2. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock trades on The NASDAQ Global Select Market under the symbol SGMO. On February&nbsp;17, 2016, the last reported sale price of
our common stock on The NASDAQ Global Select Market was $5.63. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is April 29, 2016 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONT<A NAME="toc"></A>ENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_1">ABOUT THIS PROSPECTUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_2">SPECIAL NOTE&nbsp;REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_3">ABOUT SANGAMO BIOSCIENCES, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_8">THE SECURITIES WE MAY OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_9">DESCRIPTION OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_10">DESCRIPTION OF PREFERRED STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_11">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_12">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc270346_16">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a &#147;shelf&#148; registration statement we filed with the Securities and Exchange Commission, or the SEC. By
using a shelf registration statement, we may sell any combination of securities described in this prospectus from time to time for an aggregate offering price of up to $100,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or specifically incorporated by reference into this prospectus or a prospectus
supplement. No dealer, sales person, agent or other individual has been authorized to give any information or to make any representations not contained in this prospectus. If given or made, such information or representations must not be relied upon
as having been authorized by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, the
securities offered hereby in any jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of securities. Neither the delivery of this prospectus nor any sale made hereunder
shall, under any circumstances, create an implication that there has not been any change in the facts set forth in this prospectus or in our affairs since the date of this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_2"></A>SPECIAL NOTE&nbsp;REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some statements contained in this prospectus and the information incorporated by reference into this prospectus are forward-looking with
respect to our operations, research, development and commercialization activities and financial condition. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the
outlook for the company based on currently available information. Statements that are forward-looking in nature should be read with caution because they involve risks and uncertainties, which are included, for example, in specific and general
discussions about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product development and commercialization of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnering, acquisition and other strategic transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revenues from existing and new collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our research and development and other expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sufficiency of our cash resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our operational and legal risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans, objectives, expectations and intentions and any other statements that are not historical facts </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various terms and expressions similar to them are intended to identify these cautionary statements. These terms include:
&#147;anticipates,&#148; &#147;believes,&#148; &#147;continues,&#148; &#147;could,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;seeks,&#148; &#147;should&#148; and &#147;will.&#148;
Actual results may differ materially from those expressed or implied in those statements. Factors that could cause these differences include, but are not limited to, those discussed under &#147;Risk Factors.&#148; Sangamo undertakes no obligation to
publicly release any revisions to forward-looking statements to reflect events or circumstances arising after the date of this prospectus. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of
the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZFP Therapeutic&reg; and Engineering Genetic Cures&reg; are a registered trademarks of Sangamo
BioSciences, Inc. This report also contains trademarks and trade names that are the property of their respective owners </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_3">
</A>ABOUT SANGAMO BIOSCIENCES, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company focused on the research, development and
commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation, and we are leaders in this field. Our proprietary zinc finger DNA-binding (&#147;ZFP&#148;) technology enables precise and highly specific
genome editing and gene regulation and we are developing ZFP Therapeutics, novel therapeutic products for the treatment of genetic disease. We have several proprietary clinical and preclinical programs in development and have strategically partnered
certain programs with biopharmaceutical companies to expedite clinical and commercial development. Our long-term goal is to integrate manufacturing, development and commercial operations to capture the value of our proprietary ZFP Therapeutic
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and our licensed partners, are the leaders in the research, development and commercialization of zinc finger DNA-binding
proteins, a naturally occurring class of proteins found in humans. We have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make ZFP nucleases
(&#147;ZFNs&#148;), proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes (genome editing) and ZFP transcription factors (&#147;ZFP TFs&#148;), proteins that can be used to turn genes on or off (gene
regulation). As ZFPs act at the DNA level, they potentially have broad and fundamental applications in several areas including human therapeutics, plant agriculture and research reagents, as well as production of transgenic animals and cell-line
engineering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The main focus for our company is the development of novel human therapeutics. Our lead ZFP Therapeutic, SB-728, a
ZFN-modified autologous cell product for the treatment of HIV/AIDS, is the first therapeutic application of our ZFN genome editing technology and is being evaluated in an ongoing Phase 2 study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3*) and a
Phase 1/2 study of modified hematopoietic stem cells (SB-728-mR-HSC) in HIV-infected subjects. We are also initiating Phase 1/2 studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B and MPS I, a lysosomal storage
disorder (LSD). In addition, we have proprietary preclinical programs in hemophilia A and other LSDs and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders, and cancer immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a collaborative partnership with Biogen Inc. to research, develop and commercialize our preclinical ZFP Therapeutic
development program in hemoglobinopathies, including sickle cell disease and beta-thalassemia. We also have a collaborative partnership with Shire International GmbH, formerly Shire AG, to research, develop and commercialize our preclinical ZFP
Therapeutic development program in Huntington&#146;s disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the potential commercial applications of ZFPs are broad-based
and we have entered into strategic partnerships in fields outside human therapeutics to facilitate the sale or licensing of our ZFP platform. We have a license agreement with the research reagent company Sigma-Aldrich Corporation. Under this
agreement. Sigma has the exclusive rights to develop and market high value ZFP-based laboratory research reagents marketed under the trademark CompoZr <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> as well as ZFP-modified cell lines for
commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. We also have a license agreement with Dow AgroSciences, LLC, a wholly owned subsidiary of Dow Chemical Corporation. Under this agreement, DAS has the exclusive
rights to use our ZFP technology to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures and markets our ZFN technology under the trademark EXZACT<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>
Precision Technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal offices are located at 501 Canal Boulevard, Richmond, California 94804, and our telephone number
there is (510)&nbsp;970-6000. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in the securities offered through this prospectus involves certain risks. You should carefully consider the specific risks
set forth under the caption &#147;Risk Factors&#148; in the applicable prospectus supplement and </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
under the caption &#147;Risk Factors&#148; in our filings with the Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as
amended, incorporated by reference herein, before making an investment decision. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we
currently consider immaterial may also affect our business operations. To the extent that a particular offering implicates additional significant risks, we will include a discussion of those risks in the applicable prospectus supplement. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be otherwise set forth in the prospectus supplement accompanying this prospectus, we will use the net proceeds we receive from
sales of the securities offered hereby for general corporate purposes, including support for our continuing research and development, preclinical and clinical trial activities, commercialization activities, business development activities, and, if
opportunities arise, acquisitions of businesses, products, technologies or licenses that are complementary to our business, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this
prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_6"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary is qualified by the more detailed information appearing in the computation table found in Exhibit 12.1 to the
registration statement of which this prospectus is part and the historical financial statements, including the notes to those financial statements, incorporated by reference in this prospectus. The following table sets forth our ratio of earnings to
fixed charges for each of the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ratio of earnings to fixed charges (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The ratio of earnings to fixed charges was computed by dividing earnings by fixed charges. For this purpose, earnings consist of net loss before fixed charges. Fixed charges consist of interest expense on outstanding
lease liabilities, interest expense, amortization of debt expense and discount or premium related to indebtedness, whether expensed or capitalized. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Earnings were insufficient to cover fixed charges for these periods. We have not included a ratio of earnings to combined fixed charges and preferred stock dividends because we do not have any preferred stock
outstanding as of the date of this prospectus. The amount of the coverage deficiency was $46.4 million, $26.4 million, $26.6 million, $22.3 million and $35.8 million for the years ended December&nbsp;31, 2015, 2014, 2013, 2012 and 2011,
respectively. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="toc270346_7"></A>PLAN OF DISTRIBUTION </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities being offered by us in this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to purchasers or investors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through dealers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through underwriters; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through a combination of any of these methods of sale. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our agents and underwriters may
sell the securities being offered by us in this prospectus from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at a fixed price or prices which may be changed; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by us, or by
agents designated by us, from time to time. Any such agent, which may be deemed to be an underwriter as that term is defined in the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), involved in the offer or sale of the securities
in respect of which this prospectus is delivered will be named, and any commissions payable by us to such agent will be set forth, in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an underwriter is, or underwriters are, utilized in the offer and sale of securities in respect of which this prospectus and the
accompanying prospectus supplement are delivered, we will execute an underwriting agreement with such underwriter(s) for the sale to it or them and the name(s) of such underwriter(s) and the terms of the transaction, including any underwriting
discounts, commissions and other items constituting compensation of the underwriters and dealers, if any, will be set forth in such prospectus supplement, which will be used by the underwriter(s) to make resales of the securities in respect of which
this prospectus and such prospectus supplement are delivered to the public. The securities will be acquired by the underwriters for their own accounts and may be sold by the underwriters from time to time in one or more transactions, including
negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any public offering price and any discounts, commissions or concessions allowed or reallowed or paid to dealers may be changed from time
to time. We may grant underwriters who participate in the distribution of securities an option to purchase additional securities to cover over-allotments, if any, in connection with the distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell directly to, and solicit offers from institutional investors, individuals, or the public. We will describe the terms of any such
sales in the applicable prospectus supplement relating to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect
of which this prospectus is delivered, we will sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. The name of the dealer
and the terms of the transaction will be identified in the applicable prospectus supplement relating to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an agent is used
in an offering of securities being offered by this prospectus, the agent will be named, and the terms of the agency will be described, in the applicable prospectus supplement relating to the offering. Unless otherwise indicated in the prospectus
supplement, an agent will act on a best efforts basis for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If indicated in the applicable prospectus
supplement, we will authorize underwriters or their agents to solicit offers by certain institutional investors to purchase our securities pursuant to contracts providing for payment and delivery at a future date. Institutional investors with which
these contracts may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and others. In all cases, these purchasers must be approved by us. The obligations of
any purchaser under any of these contracts will not be subject to any conditions except that (a)&nbsp;the purchase of the securities must not at the time of delivery be prohibited under the laws of any jurisdiction to which that purchaser is subject
and (b)&nbsp;if the securities are also being sold to underwriters, we must have sold to these underwriters the securities not subject to delayed delivery. Underwriters and other agents will not have any responsibility in respect of the validity or
performance of these contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters, dealers or agents utilized by us in any offering may be customers of,
including borrowers from, engage in transactions with, and perform services for us or one or more of our affiliates in the ordinary course of business. Underwriters, dealers, agents and other persons may be entitled, under agreements which may be
entered into with us, to indemnification against and contribution toward certain civil liabilities, including liabilities under the Securities Act. The terms of any indemnification provisions will be set forth in a prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the securities is completed, rules of the Securities and Exchange
Commission may limit the ability of the underwriters and certain selling group members, if any, to bid for and purchase the securities. As an exception to these rules, the representatives of the underwriters, if any, are permitted to engage in
certain transactions that stabilize the price of the securities in accordance with Regulation M, but only in the case of a fixed-price offering. Such transactions may consist of bids or purchases for the purpose of pegging, fixing or maintaining the
price of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters create a short position in the securities in connection with the offering thereof (i.e., if they
sell more securities than are set forth on the cover page of the applicable prospectus supplement), the representatives of such underwriters may reduce that short position by purchasing securities in the open market. Any such representatives also
may elect to reduce any short position by exercising all or part of any over-allotment option described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such representatives also may impose a penalty bid on certain underwriters and selling group members. This means that if the
representatives purchase securities in the open market to reduce the underwriters&#146; short position or to stabilize the price of the securities, they may reclaim the amount of the selling concession from the underwriters and selling group members
who sold those shares as part of the offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, purchases of a security for the purpose of stabilization or to reduce
a syndicate short position could cause the price of the security to be higher than it might otherwise be in the absence of such purchases. The imposition of a penalty bid might have an effect on the price of a security to the extent that it were to
discourage resales of the security by purchasers in the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters, if any, makes any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the securities. In addition, neither we nor any of the underwriters, if any, makes any representation that the
representatives of the underwriters, if any, will engage in such transactions or that such transactions, once commenced, will not be discontinued without notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each series of securities covered by this prospectus would be a new issue with no established trading market, other than our common stock
which is listed on The NASDAQ Global Select Market. Any shares of common stock sold pursuant to a prospectus supplement will be listed on The NASDAQ Global Select Market or a stock exchange on which the common stock offered is then listed, subject
(if applicable) to an official notice of issuance. Any underwriters for whom securities are sold by us for public offering and sale may make a market in the securities, but the underwriters will not be obligated to do so and may discontinue any
market making at any time without notice. The securities other than the common stock may or may not be listed on a national securities exchange or eligible for quotation or trading on The NASDAQ Global Select Market. Therefore, we cannot provide any
assurance to you concerning the liquidity of any of the securities covered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states,
the securities registered by the registration statement that includes this prospectus may be sold in those states only through licensed brokers or dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The anticipated date of delivery of the securities offered by this prospectus will be described in the applicable prospectus supplement
relating to the offering. The securities offered by this prospectus may or may not be listed on a national securities exchange or a foreign securities exchange. We cannot give any assurances that there will be a market for any of the securities
offered by this prospectus and any prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_8"></A>THE SECURITIES WE MAY OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The descriptions of the securities contained in this prospectus, together with the applicable prospectus supplement, summarize the material
terms and provisions of the various types of securities that we may offer. We will describe in the applicable prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so
indicate in a prospectus supplement, the terms of the securities may revise, amend, modify or supersede the terms we have summarized below. We will also include in the prospectus supplement information, where applicable, about material United States
federal income tax considerations relating to the securities, and the securities exchange or market, if any, on which the securities will be listed or quoted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell from time to time, in one or more offerings, one or more of the following securities:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warrants to purchase common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warrants to purchase preferred stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These securities may be offered and sold from time to
time for an aggregate offering price not to exceed $100,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be used to consummate a sale of securities
unless it is accompanied by a prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_9"></A>DESCRIPTION OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of the material terms and provisions of our common stock and each other class of our securities which qualifies or limits
our common stock, please see the applicable prospectus supplement, as well as the description of our capital stock in our Registration Statement on Form 8-A dated March&nbsp;31, 2000 which is incorporated by reference in this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_10"></A>DESCRIPTION OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law and our certificate of incorporation, our board of directors is authorized, without stockholder approval, to issue shares
of preferred stock from time to time in one or more series. Our board of directors may fix the rights, preferences, privileges and restrictions of this stock. Some of the rights, preferences and privileges that our board of directors may designate
include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms. Our board of directors may determine the number of shares constituting any series or the designation of such series. Any
or all of the rights, preferences and privileges selected by the board of directors may be greater than the rights of the common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer a specific series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the applicable
prospectus supplement and will file a copy of the certificate of designation establishing the terms of the preferred stock with the SEC. To the extent required or applicable, this description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title and stated value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares offered, the liquidation preference per share and the offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends accumulate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for any sinking fund, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for redemption, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any listing of the preferred stock on any securities exchange or market; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether preferred stock will be convertible into or exchangeable for our common stock or other of our securities, and, if applicable, the conversion or exchange price (or how it will be calculated) and conversion or
exchange period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting rights, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if appropriate, a discussion of any applicable U.S. federal income tax considerations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative ranking and preference of the preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the affairs of Sangamo; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights, limitations or restrictions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer
agent and registrar for any class or series of preferred stock will be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_11">
</A>DESCRIPTION OF DEBT SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable
prospectus supplements, summarizes the material terms and provisions of the debt securities that we may offer under this prospectus, but is not complete. We may issue debt securities, in one or more series, as either senior or subordinated debt or
as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, we will describe the particular terms of any debt securities that we may
offer in more detail in the applicable prospectus supplement. The terms of any debt securities we offer under a prospectus supplement may revise, amend, modify or supersede the terms we describe below. As of the date of this prospectus, we have no
outstanding registered debt securities. Unless the context requires otherwise, whenever we refer to the &#147;indentures,&#148; we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue any senior debt securities under the senior indenture that we will enter into with the trustee named in the senior
indenture. We will issue any subordinated debt securities under the subordinated indenture that we will enter into with the trustee named in the subordinated indenture. We have filed forms of these documents as exhibits to the registration
statement, of which this prospectus is a part, and supplemental indentures. Forms of debt securities containing the terms of the debt securities being offered, and other related documents will be filed as exhibits to the registration statement of
which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the
trustee will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We use the term &#147;trustee&#148; to refer to either the trustee under the senior indenture or the trustee under the subordinated indenture,
as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the
indentures are subject to, and qualified in their entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements related to the debt
securities that we may offer under this prospectus, as well as the complete indentures that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the senior indenture and the subordinated indenture are
identical. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of
each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in an officers&#146; certificate or by a supplement indenture. Debt securities may be
issued in separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable prospectus supplement the terms of the
series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit on the amount that may be issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depositary will be; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maturity date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if
we have to pay such additional amounts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest
payment dates or the method for determining such dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the subordination of any series of subordinated debt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the place where payments will be payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on transfer, sale or other assignment, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption
provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option, to purchase, the series
of debt securities and the currency or currency unit in which the debt securities are payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the indenture will restrict our ability or the ability of our subsidiaries to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur additional indebtedness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue additional securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">create liens; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redeem capital stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">place restrictions on our subsidiaries&#146; ability to pay dividends, make distributions or transfer assets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make investments or other restricted payments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell or otherwise dispose of assets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into sale-leaseback transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">engage in transactions with stockholders or affiliates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue or sell stock of our subsidiaries; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effect a consolidation or merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of certain material or special United States federal income tax considerations applicable to the debt securities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information describing any book-entry features; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provisions for a sinking fund purchase or other analogous fund, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the applicability of the provisions in the indenture on discharge; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an &#147;original issue discount&#148; as defined in paragraph (a)&nbsp;of Section&nbsp;1273 of the Internal
Revenue Code of 1986, as amended; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any
terms that may be required by us or advisable under applicable laws or regulations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or
exchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may
include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indentures will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of
default under the indentures with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90
days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 51% in aggregate principal amount of the outstanding debt securities of the applicable series; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if specified events of bankruptcy, insolvency or reorganization occur. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in each applicable
prospectus supplement any additional events of default relating to the relevant series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with
respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 51% in aggregate principal amount of the outstanding debt securities
of that series, by notice to us in writing, and to the trustee if notice is given </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above
occurs with respect to us, the unpaid principal, premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures, the holders of a majority in principal amount of the outstanding debt securities of an affected
series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default
in accordance with the indenture. Any waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures, if an
event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of
debt securities, unless such holders have offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority in principal amount of the outstanding debt securities of any series
will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that if an event of default has occurred and is continuing, the trustee will be required in the
exercise of its powers to use the degree of care that a prudent person would use in the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or that the trustee determines is
unduly prejudicial to the rights of any other holder of the relevant series of debt securities, or that would involve the trustee in personal liability. Prior to taking any action under the indentures, the trustee will be entitled to indemnification
against all costs, expenses and liabilities that would be incurred by taking or not taking such action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture for any series of debt securities that we may issue, we and the trustee may change an indenture without
the consent of any holders with respect to the following specific matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fix any ambiguity, defect or inconsistency in the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with the provisions described above under &#147;Description of Debt Securities &#151; Consolidation, Merger or Sale&#148;; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided under &#147;Description of Debt Securities &#151; General,&#148; to establish the form of
any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to evidence and provide for the acceptance of appointment hereunder by a successor trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for uncertificated debt securities and to make all appropriate changes for such purpose; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to our covenants such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional
covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to change anything that does not adversely affect the interests of any holder of debt securities of any series in any material respect. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indentures, the rights of holders of a series of debt securities may be
changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, subject to the terms of the indenture for any
series of debt securities that we may issue or otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each holder of any
outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extending the stated maturity of the series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that,
subject to the terms of the indenture and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we can elect to be discharged from our obligations with respect to one or more series of
debt securities, except for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer or exchange of debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">replace stolen, lost or mutilated debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain paying agencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recover excess money held by the trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensate and indemnify the trustee; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appoint any successor trustee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must
deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indentures provide
that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified in a
prospectus supplement with respect to that series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indentures and the
limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized
denomination and of like tenor and aggregate principal amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indentures and the limitations applicable to global securities set
forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by
us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we
will make no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar,
that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we
will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the
debt securities of any series, we will not be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities
that may be selected for redemption and ending at the close of business on the day of the mailing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture and is under no obligation to exercise any of the
powers given it by the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However, upon an event of default under an
indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment
and Paying Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any
debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_12"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase shares of common stock or shares of preferred stock. The warrants may be issued independently or together
with any other securities and may be attached to or separate from the other securities. Each series of warrants may be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. The
warrants will be evidenced by warrant certificates. Unless otherwise specified in the prospectus supplement, the warrant certificates may be traded separately from the securities with which the warrant certificates were issued. Warrant certificates
may be exchanged for new warrant certificates of different denominations at the office of an agent that we will appoint. Until a warrant is exercised, the holder of a warrant does not have any of the rights of a holder of our securities and is not
entitled to any payments on any securities issuable upon exercise of the warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a series of warrants will describe the specific terms of
the warrants including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price or prices at which the warrants will be issued and the currency in which the price for the warrants may be paid; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price at which and the currency in which the securities purchasable upon exercise of the warrants may be purchased and the various factors considered in determining that price; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants will commence and expire and whether the exercise of warrants will be at the option of holders, at our option, or automatic; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the warrants are exercisable by payment of cash, surrender of other securities, or both; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provisions for changes to or adjustments in the exercise price of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the series of preferred stock with which the warrants are issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the other securities with which the warrants are issued and the number of the warrants issued with each such other security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date on and after which the warrants and other related securities will be separately transferable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, any anti-dilution protection against future issuances; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the warrants will be issued in registered form or bearer form; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information with respect to book-entry procedures, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, a discussion of material U.S. federal income tax considerations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of the warrants, including terms, procedures, and limitations relating to the exchange or exercise of the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The legality of the securities offered by this prospectus has been passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP, San Francisco,
California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form 10-K for the year ended December&nbsp;31, 2015, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2015, as set forth in their reports, which are incorporated by reference in this
prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_15"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the SEC. The registration statement that contains this prospectus,
including the exhibits to the registration statement, contains additional information about us and the securities offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we file
at the SEC&#146;s Public Reference Room at 100 F. Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our public filings, including reports, proxy and information
statements, are also available on the SEC&#146;s web site at http://www.sec.gov. We maintain a website at www.sangamo.com. The information contained on our website is not incorporated by reference in this prospectus and any accompanying prospectus
supplement, and you should not consider it a part of this prospectus and any accompanying prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc270346_16">
</A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other
documents that we file with them, which means that we can disclose important information by referring to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we file later with
the SEC will automatically update and supersede this information. We incorporate by reference into this prospectus the documents listed below, and any future filings (other than the portions thereof deemed to be &#147;furnished&#148; to the SEC
pursuant to Item&nbsp;2.02 or Item&nbsp;7.01 of Current Report on Form 8-K) we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), until we have sold all of
the securities to which this prospectus relates or the offering is otherwise terminated, including any such filing prior to the effectiveness of this registration statement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our annual report on Form 10-K for the year ended December&nbsp;31, 2015, filed with the SEC on February&nbsp;18, 2016; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form 8-A filed under Section&nbsp;12(g) of the Exchange Act with the SEC on March&nbsp;31, 2000, including any amendment or reports filed
for the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any statement in this prospectus is inconsistent with any
statement that is incorporated by reference and that was made on or before the date of this prospectus, the statement in this prospectus shall supersede such incorporated statement. The incorporated statement shall not be deemed, except as modified
or superseded, to constitute a part of this prospectus or the registration statement. Statements contained in this prospectus as to the contents of any contract or other document are not necessarily complete and, in each instance, we refer you to
the copy of each contract or document filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person,
including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the information that has been incorporated into this prospectus by reference (except exhibits, unless they are
specifically incorporated into this prospectus by reference) but not delivered with this prospectus. You should direct any requests for copies to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Sangamo BioSciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">501
Canal Boulevard </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Richmond, CA 94804 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">(510)&nbsp;970-6000 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g270346tx_logo.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g270346g03f28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Sangamo BioSciences, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Cowen and
Company </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;7, 2016 </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g270346g03f28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g270346g03f28.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MM#V_P[N=2F'AGXE6%QISV,TSFUAU>QC>]LKJ&-FVQSMY31$J 6#XYQ0!O?\
M!8?X6Z/X,^//AWQGHUC%8+\0?#SW6J+!&L<4VJZ7,L$URRH /.E292Q[[.:
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M@#^4SQIK<OPO_;^U?7) 83X?^-\-Q+GY-MO<:C;K*Q)QA1!<L2?3- 'Z7?\
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MU(SFC] _0_EW^(?A6[\#>._%WA"^1XKKPWXAU7294=2C*;*\EB3((!'R*IH
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M@_9>^-TCX55\#:F#G@#<T2C]6% 'XB?\$5U?_A<?Q'(_U:^#[<-[$W;[?ZT
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MD.:/T#]#]@?^"QOC3^P?V== \,12;9O%OC*UB= <%[73[:YGE)']T.8_Q(H
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MO+O3M%U>\>TUC1;.YF>9=-TZUD8V\D4*E8U6%8RP1<Y-'Z!^A1_X)7:SX_\
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MV#L,XH GP??CV]* #!]QCTXH  ,=L8_#I0 8/H: #!]#0 8/H: #!]#0!(.
M.V/PQB@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
* "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g270346g56s59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g270346g56s59.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MX$?'VRC%SXJ^%FAZ=::XT(\R5])C9?#FO)*P!*+!=V5I=D'H">QH_0/T*/\
MP1U^,%OJT?Q._9B\52_:]&\2:3?>)O#MG<R!HPDMO_9GBG3((WXV36T\%UM'
M\22MWH ^+="U#6/V OV[YHG64Z+X0\9SZ5=J^Z--3^'GB9E42@_QK'I=U%*#
MWDL:-@V/KW_@LYX$M+W7O@U\<M"=+S1O%WAN7PY/J-OB2VN&M0NL:+,LR$J5
MET^\GV\\[.*/T#]#V'_@BE\43?>#OBK\(+Z</)H.K6'C'1('8';8:O";#58D
M0_P+>6T$A][D^M 'YR_M^? ?2_A=^V3K/AN'.C^#_B+K>B^*+">&-5BTVR\4
MWT<>L"V5@$(M;QKQ\'@$@'B@#K/CQ\!?C+_P3;^+'A+XE_"SQ?JFI>#M7,4_
MAOQE# 8+>]4".:[\*^+;.W8VTPFA)95/R31/NCVNG!L&Q_0I^Q_^U'X:_:L^
M$UAXXTN*#2_$NFR)I/C?PTDOF/HFN1QAF:$,=[Z;=1_OK>1@,J2I^:,T ?5R
M]!VQ^'2@#\6?^"O7[37B#P!X6\,? 3P5J4VD:E\2+.?5/&&IVLK07,7A6&Y^
MQ0:1%,A#0+?7:RF<@@F&#:#AS1^@?H?6O[*_[$W[/_PG^$OA!3X!\,>,/$VO
M^&=*U7Q'XL\2Z39:U?:G=:Q807T\-M]NBECM-.B\_P J**!5RB@L26X-@V/S
MB_:E_9Y\.?LD?MD_LW_&SX5Z>OASP9XZ^(6FV%_H-BC1Z;HOB#[5!:7\%B@.
M(K'4+"_DE^SYVHT,NP;2 #;RL&WE8Y7_ (*86FN_ ;]MKX2?M$:9"XL-1@\,
M:O!<(&$;:AX/NTLM6L7=1C?)IKQ/CNL_M0!]=_\ !4_X;Z?\;_V4?#'QL\+1
MI>S^!CI?C"UN( )))O"'BFVM8]0!=,Y2!Y;.8KT!C<GI1^@?H<U_P39\4:/^
MTG^QAX__ &<_%DJW=SX5MM7\)/'<MO9?#WB6&XO?#]RB,"2EEJ(F4'G'D(*
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MOAI^VM#\#?A=%J8\.P>*? .E6D&I7SZI?)=ZN-+GOT:Z90T@62Y? (RHX[4
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M\A%G\2:J+1-BC !6UMK2(8'1* /Z(_!NAVG@/X>^&?#MI$EM9^$?"&EZ:D2
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MS^)$UOMU+X@^*I[6RG9,2-I/AFW:TA5'(R8FU&>\;@X)3U% 'Y>_L7V!U?\
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M+K4]?U.RU"_EN8XK?39$CCL[I;9TBS/*44QC 88% '[(_L\?LM?![]F/PT-
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?YCZG)H =MQ^%  %Q[4 &TT &TT &TT . P/I0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g270346tx_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g270346tx_logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 8 "= P$1  (1 0,1 ?_$ 'T   (" P # 0$
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MW[BG Z38-D3@0LA)IJF.'P)FU!*]/ETYRZO,L-TS[<IN[;UQY-MIQI;)Z,M
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M%]?=$QI;*_R X-R:]:/#4^_;>HV,@)3XU/L22]0LTRUFHDB__3*[03>(.#$
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M74,<B0IMC-V)T]1$H@M_ =>@D'W$MM\KB[DFJV<DF:X57</A^ >M7OPB#?\
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MQ&(LN3\HX/K^)TLHUJ<0EZY:\3L9I2TP0,E6*JK!]I(+^971#F$4P @CH70
M0)]FQ@OM?YW=K&YVMG<1#ZRQ& LENG\>H9FNZ=8ZO"-<DR_.D*8B9S"Q1&Z@
MZZF2-XF'3H#_ /M=[;F>Y[B89[@(2(^XL^W>STS,46L"I"J,:1=&;6&NA55"
M=UR(L9-NJ!.Y1,EJ'<->@ASU8LC0>\[ARS5LWR4W0L,1C>?R+AR2B7"XB#C'
MN7(!W+1S$Q1-Y-R)O)%Z!3!VU[A^/0#<]5@S+'&[3DUXI\ZUMK/5VS0UH;SE
M/FP*M&O3XULDMC>\QKEBMK\Y9>"GVHZE$#D!$# .H:] KWRT;*+7QM[Y-PVU
M%)Y,I8Y)8VUHQ\LX.LV:VS&4RLK.41X[1*86SI>&1<G;"(B<2+(F'74P] RE
MQHHM<[>J3R48PLZAW3/"]AR'=Z^3R*8S-W&LZS?8T \]?%-*3BSG  _CVZ"E
MOJ&9]K.#^0'.)[]96U5QY+;2\D62U3,@HH2*BFN.)6OVE>7D?#R$&\="IOCB
M(%,;OH'0/!MO8=X9W2X();Z\9>8J$2#Y(JYI$$RAP3()55*X5,2B8P=]=/QZ
M "/NFRL'-[7M@%\KCY!^G+99M<O7I=OKXO8&3Q^UFHM\W\@ _P #A,Z2I=0
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M#^U2X6?U%8#&N+:ZZDKMG.XP-W!A&L3NI&7&W9KBF#AR5%, 5<?;1C4#ZZZ
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MW9%3)&^X4#P,74 T$.@--A/A=VSTK8+CKCPS[9LB[L,*8[OD9D6-;Y.L#^*
M\I"NW+Z%K96U;=L%"4.(<O%!0B3K*-@ P ("4   )CB3"6',!55"C8/Q90,2
MT]MXF3KN/JK#5>,,J4I2 X<(1+-L#MV8I0 RJOFH;ZF$1[]!*&O0>/\ 7^OX
)=!G09T&=!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
